Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Iron deficiency may impair aerobic performance. This study aimed to determine whether treatment with intravenous iron (ferric carboxymaltose) would improve symptoms in patients who had heart failure, reduced left ventricular ejection fraction, and iron deficiency, either with or without anemia. METHODS: We enrolled 459 patients with chronic heart failure of New York Heart Association (NYHA) functional class II or III, a left ventricular ejection fraction of 40% or less (for patients with NYHA class II) or 45% or less (for NYHA class III), iron deficiency (ferritin level <100 microg per liter or between 100 and 299 microg per liter, if the transferrin saturation was <20%), and a hemoglobin level of 95 to 135 g per liter. Patients were randomly assigned, in a 2:1 ratio, to receive 200 mg of intravenous iron (ferric carboxymaltose) or saline (placebo). The primary end points were the self-reported Patient Global Assessment and NYHA functional class, both at week 24. Secondary end points included the distance walked in 6 minutes and the health-related quality of life. RESULTS: Among the patients receiving ferric carboxymaltose, 50% reported being much or moderately improved, as compared with 28% of patients receiving placebo, according to the Patient Global Assessment (odds ratio for improvement, 2.51; 95% confidence interval [CI], 1.75 to 3.61). Among the patients assigned to ferric carboxymaltose, 47% had an NYHA functional class I or II at week 24, as compared with 30% of patients assigned to placebo (odds ratio for improvement by one class, 2.40; 95% CI, 1.55 to 3.71). Results were similar in patients with anemia and those without anemia. Significant improvements were seen with ferric carboxymaltose in the distance on the 6-minute walk test and quality-of-life assessments. The rates of death, adverse events, and serious adverse events were similar in the two study groups. CONCLUSIONS: Treatment with intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency, with or without anemia, improves symptoms, functional capacity, and quality of life; the side-effect profile is acceptable. (ClinicalTrials.gov number, NCT00520780).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Likewise, parenteral iron substitution has been found to improve the clinical course of CHF in patients with coexisting ID [22–24].”
From Iron deficiency or anemia of inflammation?: Differential diagnosis and mechanisms of anemia of inflammation (2016) · cites this paper as [24]
In the citing paper
“We are aware that anemia is a complication of iron deficiency, though not the only one, since other tissues/organs may be iron-depleted before anemia develops, as occurs in chronic heart failure.75”
From Iron metabolism and iron disorders revisited in the hepcidin era (2020) · cites this paper as [75]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
EQ-SD: a measure of health status from the EuroQol Group
Rabin, R., & Charro, F. D. (2001) · Annals of Medicine · doi:10.3109/07853890109002087 · Cited by 5,613
Regression Models for Ordinal Data
McCullagh, P. (1980) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1980.tb01109.x · Cited by 4,453
2005 WRITING COMMITTEE MEMBERS, Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192065 · Cited by 3,720
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008
Dickstein, K., Authors/Task Force Members, Cohen-Solal, A., Filippatos, G., McMurray, J. J. V., Ponikowski, P., Poole-Wilson, P. A., Strömberg, A., van Veldhuisen, D. J., Atar, D., et al. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.08.005 · Cited by 3,512
Self-citationGreen, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Trends in Heart Failure Incidence and Survival in a Community-Based Population
Roger, V. L. (2004) · JAMA · doi:10.1001/jama.292.3.344 · Cited by 1,600
Jessup, M., & Brozena, S. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021498 · Cited by 1,564
Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., Michl, K., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.11.013 · Cited by 1,374
Haas, J. D., & Brownlie, T. (2001) · The Journal of Nutrition · doi:10.1093/jn/131.2.676s · Cited by 1,186
Research works printed but not linked: 4
- Fairbanks V, Beutler E. Iron deficiency. In: Beutler E, ed. Williams hematology. 6th ed. New York: McGraw-Hill, 2001:295-304, 447-70.
- Davies KJ, 1982, Am J Physiol, 242, E418
- Usmanov RI, 2008, J Nephrol, 21, 236
- Ganzoni AM, 1970, Schweiz Med Wochenschr, 100, 301
Cited by
Items 901–1,000 of 1,002
Valentová, M., Anker, S. D., & von Haehling, S. (2022) · Cardiology Clinics · doi:10.1016/j.ccl.2021.12.008 · Cited by 16
Self-citationIron deficiency in Russia heart failure patients. Observational cross-sectional multicenter study
VIu, M., Begrambekova, Y. L., Mareev, Y. V., Кобалава, Ж. Д., Karapetyan, L. V., Galochkin, S. A., Kazakhmedov, E. R., Lapshin, A. A., Анатольевна, Г. А., Андреевна, К. Е., et al. (2022) · Kardiologiia · doi:10.18087/cardio.2022.5.n2083 · Cited by 14
A Panoramic View of Ferroptosis in Cardiovascular Disease
Cheng, X., Yu, C., Yang, X., Wang, F., & Min, J. (2023) · Kidney Diseases · doi:10.1159/000530046 · Cited by 14
Anaemia in chronic heart failure: more awareness is required
Pisaniello, A. D., Wong, D., Kajani, I., Robinson, K. L., & Shakib, S. (2013) · Internal Medicine Journal · doi:10.1111/imj.12195 · Cited by 16
Reed, B. N., Rodgers, J. E., & Sueta, C. A. (2014) · Heart Failure Clinics · doi:10.1016/j.hfc.2014.07.005 · Cited by 20
König, C., Kleber, M., Ihorst, G., Gropp, A., Reinhardt, H., Koch, B., Wäsch, R., & Engelhardt, M. M. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2013.06.001 · Cited by 16
Martínez‐Ruiz, A., Tornel-Osorio, P. L., Sánchez‐Más, J., Pérez-Fornieles, J., Vilchez, J. A., Martínez-Hernández, P., & Pascual-Figal, D. A. (2012) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2012.05.011 · Cited by 18
Beavers, C. J., Alburikan, K. A., Rodgers, J. E., Dunn, S. P., & Reed, B. N. (2014) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1412 · Cited by 14
Hammadah, M., Brennan, M., Wu, Y., Hazen, S. L., & Tang, W. H. W. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.01.023 · Cited by 14
Iron metabolism in solid‑organ transplantation: how far are we from solving the mystery?
Małyszko, J., Levin-Iaina, N., Myśliwiec, M., Przybyłowski, P., & Durlik, M. (2012) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.1423 · Cited by 16
Okabe, T., Yakushiji, T., Kido, T., Oyama, Y., Igawa, W., Ono, M., Ebara, S., Yamashita, K., Yamamoto, M. H., Saito, S., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.12.101 · Cited by 15
Updates in Heart Failure: What Last Year Brought to Us
Dinatolo, E., Sciatti, E., Anker, M. S., Lombardi, C., Dasseni, N., & Metra, M. (2018) · ESC Heart Failure · doi:10.1002/ehf2.12385 · Cited by 17
Intravenous Iron Therapy in Heart Failure: A Different Perspective
Ghafourian, K., Chang, H., & Ardehali, H. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1434 · Cited by 14
Reznik, E. V., & Nikitin, I. G. (2019) · The Russian Archives of Internal Medicine · doi:10.20514/2226-6704-2019-9-2-93-106 · Cited by 18
Iron i.v. in heart failure: ready for implementation?
Rocca, H. B., & Crijns, H. J. G. M. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu392 · Cited by 14
Iron deficiency in heart failure—time to redefine
Martens, P., Beverborg, N. G., & van der Meer, P. (2020) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa119 · Cited by 14
Choorapoikayil, S., Baron, D. M., Spahn, D. R., Lasocki, S., Boryshchuk, D., Yeghiazaryan, L., Posch, M., Bisbe, E., Metnitz, P., Reichmayr, M., et al. (2025) · The Lancet Global Health · doi:10.1016/s2214-109x(25)00320-1 · Cited by 17
Prevalence and Determinants of Iron Deficiency in Cardiac Amyloidosis
Duval, A. J., Bézard, M., Moutereau, S., Kharoubi, M., Oghina, S., Zaroui, A., Galat, A., Chalard, C., Hugon‐Vallet, E., Lemonnier, F., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.13818 · Cited by 12
“220 Clopidogrel, n (%) 46 (6) 12 (4) 6 (4) 28 (7) 0.”
Kvaslerud, A. B., Bardan, S., Andresen, K., Kløve, S. F., Fagerland, M. W., Edvardsen, T., Gullestad, L. L., & Broch, K. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2557 · Cited by 18
Progress and Setbacks in Translating a Decade of Ferroptosis Research into Clinical Practice
von Samson‐Himmelstjerna, F. A., Kolbrink, B., Riebeling, T., Kunzendorf, U., & Krautwald, S. (2022) · Cells · doi:10.3390/cells11142134 · Cited by 17
“Moreover, raising serum iron levels well above the normal range by regularly infusing a high dose of intravenous ferric carboxymaltose notably improves the quality of life, morbidity and re-hospitalization rate of patients with heart failure and iron deficiency [110,111].”
BackgroundGreenwood, S. A., Beckley‐Hoelscher, N., Asgari, E., Ayis, S. A., Baker, L. A., Banerjee, D., Bhandari, S., Bramham, K., Chilcot, J., Burton, J. O., et al. (2022) · BMC Nephrology · doi:10.1186/s12882-022-02896-3 · Cited by 14
“Calculations from the FAIR-HF study [27] and a study in patients with CKD [28] suggested a clinically meaningful improvement in 6MWD of up to 40 m.”
MethodGertler, C., Scherbakov, N., Freyhardt, P., Valentová, M., Aland, S. C., Walter, T., Unterberg‐Buchwald, C., Placzek, M., Ding‐Reinelt, V., Bekfani, T., et al. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14329 · Cited by 13
An Alternative Mechanism of Subcellular Iron Uptake Deficiency in Cardiomyocytes
Dai, Y., Ignatyeva, N., Xu, H., Wali, R., Toischer, K., Brandenburg, S., Lenz, C., Pronto, J. R. D., Fakuade, F. E., Sossalla, S. T., et al. (2023) · Circulation Research · doi:10.1161/circresaha.122.321157 · Cited by 14
Iron Dysregulation in Cardiovascular Diseases
Wang, H., Huang, Z., Du, C., & Dong, M. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2501016 · Cited by 20
“While it has been suggested that correction of iron deficiency before the development of anaemia may improve symptoms and quality of life [32,119], there is limited evidence to support this viewpoint.”
BackgroundBaris, R. O., & Tabit, C. E. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14165894 · Cited by 21
“In a randomized controlled trial, IV ferric carboxymaltose therapy was shown to improve symptoms and increase functional capacity in iron-deficient HFrEF patients [63].”
Management of Comorbid Conditions in Heart Failure
Nagarajan, V., & Tang, W. H. W. (2012) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.07.006 · Cited by 17
Anemia and iron-restricted erythropoiesis in traumatic critical illness
Pirie, K., Myles, P. S., & Wood, E. M. (2015) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0000000000000939 · Cited by 14
Drug therapies in chronic heart failure: a focus on reduced ejection fraction
Bolam, H., Morton, G., & Kalra, P. R. (2018) · Clinical Medicine · doi:10.7861/clinmedicine.18-2-138 · Cited by 16
Insight Into the Potential Value of Gut Microbial Signatures for Prediction of Gestational Anemia
Wei, H., Deng, S., Qin, Y., Xu, Y., Chen, T., Wang, X., & Xia, Y. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.734561 · Cited by 15
“Furthermore, it has been reported that babies born to anemic mothers are prone to exhibit future poor cognitive performance and delayed mental and motor development in adolescence and adulthood (Anker et al., 2009; Camaschella, 2015).”
BackgroundHuguet, J. M., Cortés, X., Boscá-Watts, M. M., Muñoz, M., Maroto, N., Iborra, M., Hinojosa, E., Capilla, M., Asencio, C., Amorós, C., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11102786 · Cited by 13
Rationale and design of a randomised trial of intravenous iron in patients with heart failure
Kalra, P. R., Cleland, J. G. F., Petrie, M. C., Ahmed, F. Z., Foley, P. W. X., Kalra, P. A., Lang, N. N., Lane, R., Macdougall, I. C., Pellicori, P., et al. (2022) · Heart · doi:10.1136/heartjnl-2022-321304 · Cited by 13
Dickson, E. A., Ng, O., Keeler, B. D., Wilcock, A., Brookes, M., & Acheson, A. G. (2023) · Palliative Medicine · doi:10.1177/02692163221145604 · Cited by 13
The Role of Micronutrients and Macronutrients in Patients Hospitalized for Heart Failure
Trippel, T. D., Anker, S. D., & von Haehling, S. (2013) · Heart Failure Clinics · doi:10.1016/j.hfc.2013.05.001 · Cited by 14
Self-citationUpdate on intravenous iron choices
Larson, D. S., & Coyne, D. W. (2014) · Current Opinion in Nephrology & Hypertension · doi:10.1097/01.mnh.0000441154.40072.2e · Cited by 13
Correcting Anemia in Heart Failure: The Efficacy and Safety of Erythropoiesis-Stimulating Agents
Lawler, P. R., Filion, K. B., & Eisenberg, M. J. (2010) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2010.03.013 · Cited by 15
Vandemergel, X., & Vandergheynst, F. A. (2014) · Case Reports in Endocrinology · doi:10.1155/2014/843689 · Cited by 15
Engelhardt, M. M., Udi, J., Kleber, M., Spencer, A. G., Rocci, A., Knop, S. T., Bruno, B., Bringhen, S., Pérez‐Simón, J. A., Zweegman, S., et al. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.516378 · Cited by 13
Cinética de la hemoglobina y pronóstico a largo plazo en insuficiencia cardiaca
Díez‐López, C., Lupón, J., de Antonio, M., Zamora, E., Domingo, M., Santesmases, J., Troya, M. I., Boldo, M., & Bayés‐Genís, A. (2016) · Revista Española de Cardiología · doi:10.1016/j.recesp.2016.02.033 · Cited by 16
Büyükyazı, G., Ulman, C., Çelik, A., Çetinkaya, C., Şişman, A. R., Çımrın, D., Doğru, Y., & Kaya, D. (2017) · Physiology International · doi:10.1556/2060.104.2017.1.7 · Cited by 15
Rognoni, C., Ortalda, V., Biasi, C., & Gambaro, G. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01089-z · Cited by 16
Delgado, J. F., Oliva, J., Franco, Á. G., Cepeda, J. M., García-García, J. Á., Domínguez, A. G., García-Casanovas, A., Merino, S. J., & Colet, J. C. (2020) · Journal of Medical Economics · doi:10.1080/13696998.2020.1838872 · Cited by 13
Tu, S. J., Elliott, A. D., Hanna‐Rivero, N., Gallagher, C., Mishima, R. S., Lyrtzis, E., Wlochowicz, D., Clarke, N., Roberts‐Thomson, K. C., Stokes, M. B., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-047642 · Cited by 15
Anemia, heart failure and clinical management
Pereira, C. A., Roscani, M. G., Bazan, S. G. Z., & Matsubara, B. B. (2013) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20130126 · Cited by 20
Akute und chronische Herzinsuffizienz
Kresoja, K., Schmidt, G., Kherad, B., Krackhardt, F., Spillmann, F., & Tschöpe, C. (2017) · Herz · doi:10.1007/s00059-017-4613-y · Cited by 15
Management of Iron Deficiency in Heart Failure
Zusman, O., Zadok, O. I. B., & Gafter‐Gvili, A. (2019) · Acta Haematologica · doi:10.1159/000496822 · Cited by 15
Definition of functional iron deficiency and intravenous iron supplementation
Eisenga, M. F., Bakker, S. J. L., & Gaillard, S. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)30152-1 · Cited by 13
New concepts in iron deficiency anaemia
Keshav, S., & Stevens, R. (2016) · British Journal of General Practice · doi:10.3399/bjgp17x688465 · Cited by 16
Tereshchenko, S. N., Жиров, И. В., Uskach, T. M., Saidova, M. A., Sp, G., Михайловна, Г. Е., Николаевна, Н. С., Narusov, O. Y., Safiullina, A. A., Tereshchenko, A. S., et al. (2020) · Eurasian heart journal · doi:10.38109/2225-1685-2020-3-6-76 · Cited by 13
Hematinic and Iron Optimization in Peri-operative Anemia and Iron Deficiency
Miles, L. F., & Richards, T. (2022) · Current anesthesiology reports · doi:10.1007/s40140-021-00503-z · Cited by 16
Chronic Fatigue Syndrome in Patients with Deteriorated Iron Metabolism
Świątczak, M., Młodziński, K., Sikorska, K., Raczak, A., Lipiński, P., & Daniłowicz‐Szymanowicz, L. (2022) · Diagnostics · doi:10.3390/diagnostics12092057 · Cited by 25
“5 g/dl, aimed to evaluate the efficacy of iron supplementation in improving CHF symptoms, including fatigue in patients with iron deficiency [74].”
BackgroundInfluentialIron status in chronic inflammatory disease: therapeutic implications
Cappellini, M. D., Scaramellini, N., & Motta, I. (2023) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16430 · Cited by 14
Shi, R., Marin, J., & Beaulieu, M. (2023) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581231165705 · Cited by 12
Bhatia, K., Sabharwal, B., Gupta, K., Lopez, P. D., Kaur, A., Bhatia, H. K., Gandhi, K., Niroula, S., Correa, A. A., Birati, E. Y., et al. (2023) · Journal of Cardiology · doi:10.1016/j.jjcc.2023.06.012 · Cited by 11
Obradović, D., Loncar, G., Zeymer, U., Pöss, J., Feistritzer, H., Freund, A., Jobs, A., Fuernau, G. F., Desch, S., Ceglarek, U., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3099 · Cited by 17
Self-citationIron deficiency and all-cause mortality after myocardial infarction
Jenča, D., Melenovský, V., Mrázková, J., Šramko, M., Kotrč, M., Želízko, M., Adámková, V., Pitha, J. V., Kautzner, J., & Wohlfahrt, P. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.04.020 · Cited by 15
Anker, S. D., Friede, T., Butler, J., Talha, K. M., Diek, M., Nosko, A., Placzek, M., Hasenfuss, G. P., Ponikowski, P. P., & Karakas, M. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3574 · Cited by 15
Self-citationChan, B., Varghese, A., Badve, S. V., Pecoits‐Filho, R., Guedes, M. H., Arnott, C. G., Kozor, R., O’Lone, E., Jun, M., Kotwal, S. S., et al. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.01.029 · Cited by 16
PAHFRAC-01 investigators, Bernabeu‐Wittel, M., Aparicio, R., Romero-Jiménez, M. J., Murcia‐Zaragoza, J., Monte‐Secades, R., Rosso-Fernández, C. M., Montero, A., Ruiz‐Cantero, A., & Melero‐Bascones, M. (2012) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-13-27 · Cited by 12
Management Strategies for Heart Failure with Preserved Ejection Fraction
Vazir, A., & Solomon, S. D. (2014) · Heart Failure Clinics · doi:10.1016/j.hfc.2014.07.004 · Cited by 13
Roubille, F., Morena-Carrere, M., Leray‐Moragues, H., Canaud, B., Cristol, J., & Klouche, K. (2014) · Blood Purification · doi:10.1159/000361061 · Cited by 14
Narrative Review: The Management of Acute Decompensated Heart Failure
Marik, P. E., & Flemmer, M. C. (2011) · Journal of Intensive Care Medicine · doi:10.1177/0885066611403260 · Cited by 13
Szczech, L. A., Bregman, D. B., Harrington, R. A., Morris, D., Butcher, A., Koch, T. A., Goodnough, L. T., Wolf, M. S., & Onken, J. E. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq218 · Cited by 12
Predictors of Long-Term Mortality in Patients Hospitalized in an Intensive Cardiac Care Unit
Uścińska, E., Sobkowicz, B., Lisowska, A., Sawicki, R., Dąbrowska, M., Szmitkowski, M., Musial, W. J., & Tycińska, A. (2015) · International Heart Journal · doi:10.1536/ihj.15-249 · Cited by 12
A Blueprint for the Post Discharge Clinic Visit after an Admission for Heart Failure
Soufer, A., Riello, R. J., Desai, N. R., Testani, J. M., & Ahmad, T. (2017) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2017.08.004 · Cited by 12
Morgan, P. N., Coleman, P. L., Martínez‐Garduño, C. M., Gunaratne, A. W., McInnes, E., & Middleton, S. (2018) · Journal of Blood Medicine · doi:10.2147/jbm.s157571 · Cited by 12
“Iron infusions are a more effective treatment for iron deficiency anemia because they correct levels more quickly than oral iron.(10,29,30) The iron infusion can take effect between 2 and 6 weeks compared to oral intake that can require on average 6 weeks.”
Improving Anemia in Inflammatory Bowel Disease: Impact of the Anemia Care Pathway
Qureshi, T. M., Nguyen, T. P., Wang, R., Willis, D., Shah, R., & Hou, J. K. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05559-w · Cited by 13
Lobbes, H., Dehos, J., Pereira, B., Guenno, G. L., Sarry, L., & Ruivard, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111876 · Cited by 12
“ID leads to disability through impairment of cognitive function [5], functional capacity, and quality of life [6,7], and it can be improved by iron supplementation.”
BackgroundPark, S. M., Lee, S. Y., Jung, M., Youn, J., Kim, D., Cho, J. Y., Cho, D., Hyun, J., Cho, H., Park, S., et al. (2023) · Korean Circulation Journal · doi:10.4070/kcj.2023.0114 · Cited by 12
Empfehlung zur Herzinsuffizienz: Was gibt es Neues?
Hasenfuss, G. P., Edelmann, F., & Wachter, R. (2013) · Der Internist · doi:10.1007/s00108-013-3312-x · Cited by 13
Heart Failure and Iron Deficiency Anemia in Italy: Results From CARMES-1 Registry
Caira, C., Ansalone, G., Mancone, M., Canali, E., Pagliaro, M., Fratarcangeli, L., Aznaràn, C. A. C., Gatto, M. C., Pietro, R. D., & Fedele, F. (2013) · Future Cardiology · doi:10.2217/fca.13.12 · Cited by 13
Role of Intravenous Ferric Carboxy-maltose in Pregnant Women with Iron Deficiency Anaemia
Vineet, M., V, Gandhi, K., Roy, R., Hokabaj, S., & Shah, K. N. (2017) · Journal of Nepal Health Research Council · doi:10.3126/jnhrc.v15i2.18158 · Cited by 12
Lasocki, S., Puy, H., Mercier, G., Lehmann, S., Asfar, P., Mercat, A., Gaillard, T., Gergaud, S., Lasocki, S., Sargentini, C., et al. (2017) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2017.04.009 · Cited by 16
“Correcting ID in the presence or absence of anaemia has been found to improve patients’ resistance to exercise and/or to decrease their fatigue [21, 22].”
BackgroundPathophysiology of Chronic Systolic Heart Failure. A View from the Periphery
Katz, S. D. (2018) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201710-789kv · Cited by 16
Influence of mitochondrial and systemic iron levels in heart failure pathology
Lupu, M., Tudor, D. V., & Filip, G. A. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09788-z · Cited by 13
Rheude, T. A., Pellegrini, C., Lessmann, L., Wiebe, J., Mayr, N. P., Michel, J., Trenkwalder, T., Kasel, A. M., Schunkert, H., Kastrati, A., et al. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.07.051 · Cited by 14
Anaemia and iron dysregulation: untapped therapeutic targets in chronic lung disease?
Patel, M. S., McKie, E., STEINER, M. C., Pascoe, S. J., & Polkey, M. I. (2019) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2019-000454 · Cited by 15
“The FAIR-HF Trial, 66 67 a multicentre, randomised, double-blind, placebo-controlled trial of intravenous ferric carboxymaltose for symptomatic patients with heart failure and iron deficiency anaemia, found a 1 class improvement in New York Heart Association was 2.40-fold more likely to occur (95%…”
InfluentialAdvances in the Management of Acute Decompensated Heart Failure
Mitter, S. S., & Pinney, S. (2020) · Medical Clinics of North America · doi:10.1016/j.mcna.2020.03.002 · Cited by 16
A review of the management of patients with advanced heart failure in the intensive care unit
Cheshire, C., Bhagra, C., & Bhagra, S. K. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-1048 · Cited by 12
“There is strong evidence to recommend the use of intravenous iron in iron deficient HF patients to improve exercise capacity and symptoms (10,69).”
BackgroundDashwood, A. M., Vale, C., Laher, S., Chui, F., Hay, K. E., & Wong, Y. W. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1754 · Cited by 12
Accurate Noninvasive Assessment of Myocardial Iron Load in Advanced Heart Failure Patients
Leszek, P., Sochanowicz, B., Brzóska, K., Kraj, L., Kuśmierczyk, M., Śmigielski, W., Rywik, T. M., Sobieszczańska‐Małek, M., Rozentryt, P., & Kruszewski, M. K. (2020) · Disease Markers · doi:10.1155/2020/8885189 · Cited by 12
Wischmann, P., Chennupati, R., Solga, I., Funk, F., Becher, S., Gerdes, N., Anker, S. D., Kelm, M., & Jung, C. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13639 · Cited by 12
“These data support that iron catalysis is involved in the production of oxygen-derived free radicals during I/R injury.(11,14) In contrast, iron application in chronic ischaemic HF appears beneficial.”
BackgroundSelf-citationToblli, J. E., Rivas, C., Cao, G., Giani, J. F., Funk, F., Mizzen, L., & Dominici, F. P. (2014) · Chemotherapy Research and Practice · doi:10.1155/2014/570241 · Cited by 12
Iron Deficiency and Heart Disease: Ironclad Evidence?
Carson, J. L., & Adamson, J. W. (2010) · Hematology · doi:10.1182/asheducation-2010.1.348 · Cited by 12
Reim, D., Kim, Y., Nam, B., Kim, M., Yook, J. H., Park, Y. K., Roh, S. H., Yu, W., & Bae, J. M. (2014) · Trials · doi:10.1186/1745-6215-15-111 · Cited by 12
Vullaganti, S., Goldsmith, J., Teruya, S. L., Alvarez, J., Helmke, S. T., & Maurer, M. S. (2014) · PubMed Central · doi:10.3969/j.issn.1671-5411.2014.02.002 · Cited by 12
Mineral and bone disorders in conventional hemodialysis: Challenges and solutions
Hamano, T. (2018) · Seminars in Dialysis · doi:10.1111/sdi.12729 · Cited by 12
Myocardial Infarction and the Fine Balance of Iron
Dharmakumar, R., Nair, A. R., Kumar, A., & Francis, J. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.06.004 · Cited by 12
“Recent studies have shown that in these patients, although ferric iron infusions can reduce heart failure hospitalizations (2), iron supplementation in the same patients has failed to improve mortality (1).”
BackgroundNishigori, M., Yagi, H., Mochiduki, A., & Minamino, N. (2016) · Biopolymers · doi:10.1002/bip.22809 · Cited by 12
Iron Dyshomeostasis and Mitochondrial Function in the Failing Heart: A Review of the Literature
Mousavi‐Aghdas, S. A., Farashi, E., & Naderi, N. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00619-z · Cited by 15
“The FAIR-HF trial was the first to demonstrate that adding ferric carboxymaltose (FCM) to the treatment was associated with improved 6-min walk distance (6MWD) and QoL in chronic HF patients with evidence of ID; however, the survival and adverse events were similar with the placebo groups [146].”
Adjusting Current Hemoglobin Thresholds: A Way to Improve Outcome in Women Undergoing Major Surgery
Netz, A., Hof, L., Rumpf, F., Blum, L. V., Neef, V., Kerner, A., Zacharowski, K. D., Meybohm, P., & Choorapoikayil, S. (2024) · Journal of Women s Health · doi:10.1089/jwh.2023.0665 · Cited by 16
Wahid, M., Islam, S., Sepehrvand, N., Dover, D. C., McAlister, F. A., Kaul, P., & Ezekowitz, J. A. (2024) · Circulation Heart Failure · doi:10.1161/circheartfailure.123.011351 · Cited by 17
An Updated Review of the Management of Chronic Heart Failure in Patients with Chronic Kidney Disease
Tumelty, E. H., Chung, I., Hussain, S. A., Ali, M. A., Addada, H., & Banerjee, D. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2504144 · Cited by 13
“…in a series of RCT’s, including Ferric carboxymaltose Assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) [209], Ferric CarboxymaltOse evalua-tioN on perFormance in patients with IRon deficiency in coMbination with chronic Heart Failure (CONFIRM-HF) [210],…”
BackgroundIron Deficiency in New Onset Heart Failure: Association with Clinical Factors and Quality of Life
Cabrera, C. C., Ekström, M., Tornvall, P., Löfström, U., Frisk, C., Linde, C. M., Hage, C., Persson, H., Eriksson, M. J., Wallén, H., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14849 · Cited by 12
Foley, P. W. X., Kalra, P. R., Cleland, J. G. F., Petrie, M. C., Kalra, P. A., Squire, I., Campbell, P., Chapman, C., Donnelly, P. M., Graham, F. J., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3504 · Cited by 15
Anemia in cardiorenal disease: From pathogenesis to treatment
Heng, J., Li, Z.-T., Yao, D., Li, X., Cui, M., & Li, Z.-L. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.106506 · Cited by 11
Management of Chronic Cardiorenal Syndrome
Attanasio, P., Ronco, C., Anker, M. S., Ponikowski, P. P., & Anker, S. D. (2010) · Contributions to nephrology · doi:10.1159/000313751 · Cited by 10
Self-citationHeart failure comorbidities at the end of life
Tevendale, E., & Baxter, J. K. (2011) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0b013e32834d2ee4 · Cited by 14
González, R. S., la Vega, H. G. T., Alonso, L. M., Revuelta, S. I., & Martín, A. F. (2015) · Medicina Clínica · doi:10.1016/j.medcli.2014.10.016 · Cited by 11
Sajeev, C. G., Nair, S. R., George, B., Rajesh, G. N., & Krishnan, M. N. (2016) · ESC Heart Failure · doi:10.1002/ehf2.12119 · Cited by 12
Doehner, W., Blankenberg, S., Erdmann, E., Ertl, G., Hasenfuss, G. P., Landmesser, U., Pieske, B. M., Schieffer, B., Schunkert, H., von Haehling, S., et al. (2017) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0043-100900 · Cited by 12
Self-citation
Metadata
- Authors
- Anker, S. D., Comin Colet, J., Filippatos, G., Willenheimer, R., Dickstein, K., Drexler, H., Lüscher, T. F., Bart, B., Banasiak, W., Niegowska, J., Kirwan, B.-A., Mori, C., von Eisenhart Rothe, B., Pocock, S. J., Poole-Wilson, P. A., & Ponikowski, P.
- Affiliations
- Stavanger University Hospital (NO)
- Lund University (SE)
- University of Bergen (NO)
- Medizinische Hochschule Hannover (DE)
- University Hospital Zurich (CH)
- Pirogov Russian National Research Medical University (RU)
- State Oil Company of Azerbaijan Republic (Azerbaijan) (AZ)
- Vifor Pharma (Switzerland) (CH)
- London School of Hygiene & Tropical Medicine (GB)
- Imperial College London (GB)
- Wroclaw Medical University (PL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-12-17
- Volume
- 361
- Issue
- 25
- Pages
- 2436-2448
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2148669301
- Cited by
- 2,083
- References
- 26
- Citations by year
- 2026: 101 · 2025: 131 · 2024: 145 · 2023: 156 · 2022: 162 · 2021: 190 · 2020: 128 · 2019: 129 · 2018: 113 · 2017: 133 · 2016: 101 · 2015: 115 · 2014: 102 · 2013: 93 · 2012: 106
- FWCI
- 62.22
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- ABACUS. Repositorio de Producción Científica (Universidad Europea) (submittedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Lund University Publications (Lund University) (submittedVersion, other-oa)
- University of Bedfordshire Repository (University of Bedfordshire) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Amgen
- Teva Pharmaceutical Industries
- Vifor Pharma
- Servier
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- ferric carboxymaltose, intravenous iron, chronic heart failure, iron deficiency, anemia, reduced left ventricular ejection fraction, NYHA functional class, symptom improvement, functional capacity, 6-minute walk test, health-related quality of life, ferritin, transferrin saturation, adverse events, mortality, serious adverse events, iron deficiency anemia
- MeSH terms
- Iron Deficiencies, Aged, Chronic Disease, Female, Ferric Compounds, Ferritins, Follow-Up Studies, Heart Failure, Hematinics, Humans, Male, Maltose, Quality of Life, Stroke Volume, Ventricular Dysfunction, Left, Anemia, Iron-Deficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.